Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the Kennedy Institute of Rheumatology, NDORMS have identified a new target for treatment of particular inflammatory conditions, with the findings published this week in PNAS.

Blocking the protein interferon regulatory factor 5 (IRF5) would significantly reduce inflammation in certain chronic conditions, providing a more specific and effective treatment for patients, as well as fewer side effects from long-term use of current options.

Macrophages and neutrophils, two types of white blood cells, are the most abundant inflammatory cells in diseases driven by inflammation, like rheumatoid arthritis and acute lung injury. Each cell type can play opposing roles, with some macrophages increasing inflammation whilst other macrophages are helping to decrease it. Reducing the presence of these cells in inflamed areas, or switching their function to a ‘repair’ one, typically leads to profound therapeutic benefit.

IRF5 is very important in defining which role macrophages will play, as well as in neutrophil recruitment to affected areas, namely on acute lung injury, making it a great target for new therapies.

Kennedy researcher Miriam Weiss said: "These data highlight IRF5 as a very interesting drug target to treat inflammatory diseases such as rheumatoid arthritis. The next step will be to find ways to block this pathway, so we can move closer to an effective therapy."

You can read the full article here.

Image: neutrophils detected within the synovial capsule of inflamed knees. Left: control group; right: blocking IRF5.

Similar stories

Vaccine developed to treat osteoarthritic pain

Publication Research oacentre

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.

New drug class could offer a targeted safer treatment alternative for patients with rheumatoid arthritis

Publication Research

A new treatment targeting tenascin-C could reduce the progression and severity of rheumatoid arthritis (RA) at the very early stages of disease.

Study suggests immune system plays key role in survival after pancreatic cancer surgery

Publication Research

Researchers in Oxford have found that an individual’s immune system – and in particular the presence of T-cells amongst tumour cells – may play an important role in survival after surgery to remove pancreatic cancer.

New hope for patients with incurable and disabling Dupuytren’s disease

Publication Research

Scientists in the Kennedy Institute, NDORMS show anti-TNF inhibits the cells responsible for Dupuytren’s disease.

New method to study the behaviour of soluble molecules in tissues

Publication Research

Researchers at the Kennedy Institute and the University of York develop a new imaging approach that offers superior resolution to track the movement of soluble proteins in tissues.

Immune cells are natural networkers

Publication Research

New research published in Cell Reports by the Dustin Group has discovered a new way for immune cells to relay information about infection or genetic mutations through dynamic, yet durable cell contacts before deciding how to respond.